{"id":4671,"date":"2025-03-31T18:12:16","date_gmt":"2025-03-31T18:12:16","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/rosuvastatin-txt\/"},"modified":"2025-03-31T18:12:16","modified_gmt":"2025-03-31T18:12:16","slug":"rosuvastatin-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/rosuvastatin-txt\/","title":{"rendered":"rosuvastatin.txt"},"content":{"rendered":"<p><H3>  CLINICAL USE <\/H3><br \/>\nHMG CoA reductase inhibitor:Hyperlipidaemia <H3> DOSE IN NORMAL RENAL FUNCTION  <\/H3>5\u201340 mg daily Asians, people at increased risk of  myopathy, and in combination with fibrates: 5\u201320 mg daily<H3>  PHARMACOKINETICS    <\/H3><LI> Molecular weight &amp;nbsp  &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp  &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp :1001.1 (as calcium salt)<\/li>\n<li>  %Protein binding  &amp;nbsp &amp;nbsp &amp;nbsp  &amp;nbsp  &amp;nbsp  &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp :90<\/li>\n<li>  %Excreted unchanged in urine &amp;nbsp &amp;nbsp : 5<\/li>\n<p><LI> Volume of distribution (L\/kg) &amp;nbsp &amp;nbsp &amp;nbsp :134 litres<\/li>\n<p><LI>half-life \u2013 normal\/ESRD (hrs)&amp;nbsp &amp;nbsp &amp;nbsp :19\/Increased<H3>  DOSE IN RENAL IMPAIRMENT <\/H3> <H4>GFR (mL\/MIN)<\/H4>20\u201360 5\u201320 mg daily<LI> 10 to 20  &amp;nbsp &amp;nbsp : 5\u201320 mg daily<LI> &lt;10 &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp : 5\u201320 mg daily<H3> DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES  <\/H3><LI> CAPD  &amp;nbsp &amp;nbsp &amp;nbsp  &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp:Unlikely dialysability. Dose as in GFR &lt;10 mL\/min. <\/p>\n<li> HD &amp;nbsp  &amp;nbsp &amp;nbsp  &amp;nbsp &amp;nbsp  &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp :Not dialysed. Dose as in GFR &lt;10 mL\/min <LI>HDF\/high flux  &amp;nbsp :Unknown dialysability. Dose as in GFR &lt;10 mL\/min<LI>CAV\/VVHD  &amp;nbsp &amp;nbsp &amp;nbsp:Unknown dialysability. Dose as in GFR 10 to 20   mL\/min <H3> IMPORTANT DRUG INTERACTIONS  <\/H3>Potentially hazardous interactions with other drugs\n<li>Antibacterials: erythromycin reduces  concentration of rosuvastatin; increased risk of myopathy with daptomycin\n<li>Anticoagulants: effect of coumarins and  phenindione enhanced\n<li>Ciclosporin: increased risk of myopathy \u2013  avoid concomitant useLipid-lowering agents: increased risk of  myopathy with fibrates, gemfibrozil (avoid) and nicotinic acid<H3> ADMINISTRATION  <\/H3><H4> Reconstition<\/H4>\u2013<H4>  Route  <\/H4>Oral <H4>  Rate of Administration  <\/H4>\u2013<H4>Comments<\/H4>\u2013<H4>  OTHER INFORMATION  <\/H4>In renal impairment, doses above 20 mg  should not be used due to risk of myopathyDo not use doses greater than 20 mg in  Asian patientsAlways start at a dose of 5 mg The 40 mg dose should only be used under  specialist supervisionIncreased risk of proteinuria with doses  above 40 mgCase studies from Glasgow have shown  that statins in combination with fusidic acid have an increased risk of causing myopathy in diabetic patients.<br \/>\n","protected":false},"excerpt":{"rendered":"<p>CLINICAL USE HMG CoA reductase inhibitor:Hyperlipidaemia DOSE IN NORMAL RENAL<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4671","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4671","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4671"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4671\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4671"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4671"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4671"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}